CeriBell (NASDAQ:CBLL) VP David Foehr Sells 993 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 993 shares of CeriBell stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $24.02, for a total transaction of $23,851.86. Following the sale, the vice president directly owned 36,758 shares in the company, valued at $882,927.16. The trade was a 2.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David Foehr also recently made the following trade(s):

• On Monday, August 24th, David Foehr sold 859 shares of CeriBell stock. The stock was sold at an average price of $23.95, for a total transaction of $20,573.05.

CeriBell Stock Performance

CeriBell stock traded up $0.01 during midday trading on Tuesday, reaching $23.95. 243,381 shares of the company traded hands, compared to its average volume of 457,237. The business has a 50 day moving average of $19.77 and a two-hundred day moving average of $19.27. CeriBell, Inc. has a 12 month low of $10.85 and a 12 month high of $25.33. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. The firm has a market capitalization of $919.20 million, a price-to-earnings ratio of -13.61 and a beta of 0.81.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The business had revenue of $28.10 million during the quarter, compared to analysts’ expectations of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. As a group, research analysts predict that CeriBell, Inc. will post -1.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CBLL. Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Barclays raised shares of CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. BTIG Research upped their price objective on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Finally, Canaccord Genuity Group boosted their price target on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, CeriBell currently has an average rating of “Moderate Buy” and an average price target of $22.40.

Hedge Funds Weigh In On CeriBell

Large investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in shares of CeriBell during the second quarter valued at $37,657,000. Vanguard Group Inc. increased its position in shares of CeriBell by 11.1% in the third quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after acquiring an additional 147,013 shares in the last quarter. KCM Capital Inc boosted its position in CeriBell by 40.0% during the 1st quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock worth $25,662,000 after acquiring an additional 400,000 shares during the period. Yu Fan increased its stake in shares of CeriBell by 10.7% during the 2nd quarter. Yu Fan now owns 1,353,166 shares of the company’s stock worth $25,345,000 after purchasing an additional 130,964 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in CeriBell by 1,945.9% during the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock valued at $26,797,000 after purchasing an additional 1,162,200 shares during the last quarter.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.